5:15 PM
 | 
Jan 20, 2012
 |  BC Extra  |  Company News

EMA committee reviewing Gilenya safety

EMA's CHMP began reviewing the safety of Gilenya fingolimod from Novartis AG (NYSE:NVS; SIX:NOVN) following reports of serious cardiovascular events in patients receiving the multiple sclerosis drug, as well as the unexplained death of a U.S. patient less than...

Read the full 185 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >